Off-market insider buying at Hemostemix (HEM)

Off-market insider buying at Hemostemix (V:HEM)

Peter Alan Lacey, a Director, acquired 10,000,000 Common Shares on a direct ownership basis at a price of $0.010 through a private transaction on November 25th, 2020. The insider also acquired 10,000,000 Warrants with an exercise price of $0.050 until November 25th, 2021. This represents a $100,000 investment into the company's shares and an account share holdings change of greater than 100%.

Hemostemix is in the Biotechnology & Medical Research Sub Industry Group under the Healthcare Sector.

Hemostemix Inc is a Canada-based clinical-stage biotechnology company. The Company's principal business is to develop, manufacture and commercialize blood-derived cell therapies for medical conditions, including critical limb ischemia (CLI). The Company's clinical-stage candidate, ACP-01, is an autologous cell therapy for the treatment of CLI. ACP-01 is in a Phase II clinical trial in Canada, South Africa and the United States. The Company also focuses on developing other cell products, such as bone cell precursors (BCPs), myocardial cell precursors (MCPs) and neural cell precursors (NCPs). It operates in Canada and Israel. The Company has approximately 2,200 square foot research and manufacturing facility in Ness Ziona, Israel. Hemostemix Limited is the subsidiary of the Company.